Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
NewsPartner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. COR
stocks logo

COR

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
83.63B
+5.8%
3.813
+14.15%
86.47B
+6.11%
4.086
+9.54%
79.95B
+5.96%
4.861
+9.97%
Estimates Revision
The market is revising Downward the revenue expectations for Cencora, Inc. (COR) for FY2025, with the revenue forecasts being adjusted by -0.04% over the past three months. During the same period, the stock price has changed by 0.75%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.18%
In Past 3 Month
Stock Price
Go Up
up Image
+0.75%
In Past 3 Month
11 Analyst Rating
up Image0
Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 334.00 USD with a low forecast of 300.00 USD and a high forecast of 355.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
2 Hold
0 Sell
Strong Buy
up Image0
Current: 285.130
sliders
Low
300.00
Averages
334.00
High
355.00
up Image0
Current: 285.130
sliders
Low
300.00
Averages
334.00
High
355.00
Morgan Stanley
Erin Wright
Equal Weight
maintain
$313 -> $330
2025-07-16
Reason
Morgan Stanley
Erin Wright
Price Target
$313 -> $330
2025-07-16
maintain
Equal Weight
Reason
Morgan Stanley analyst Erin Wright raised the firm's price target on Cencora to $330 from $313 and keeps an Equal Weight rating on the shares.
Jefferies
Hold
maintain
$275 -> $300
2025-06-30
Reason
Jefferies
Price Target
$275 -> $300
2025-06-30
maintain
Hold
Reason
Jefferies raised the firm's price target on Cencora to $300 from $275 and keeps a Hold rating on the shares. Progress with the pending reconciliation bill and changes Congress has to make to get it over the line in the next few weeks will continue to drive daily trading for most healthcare provider names in the near-term, the analyst tells investors in a research note. The firm views any improvement vs. the Senate Finance Committee version of Medicaid cuts positively for its coverage universe.
Wells Fargo
Equal Weight -> Overweight
upgrade
$274 -> $337
2025-06-03
Reason
Wells Fargo
Price Target
$274 -> $337
2025-06-03
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded Cencora to Overweight from Equal Weight with a price target of $337, up from $274.
Wells Fargo
Equal Weight -> Overweight
upgrade
$274 -> $337
2025-06-03
Reason
Wells Fargo
Price Target
$274 -> $337
2025-06-03
upgrade
Equal Weight -> Overweight
Reason
As previously reported, Wells Fargo upgraded Cencora to Overweight from Equal Weight with a price target of $337, up from $274. The firm says that valuation is justified by robust industry backdrop/high estimate achievability and less relative exposure to macro/policy risks. Wells' estimates are generally in-line with consensus but assume much slower U.S. Healthcare growth and takes a fulsome approach to estimating potential impact from M&A driven customer loss, which likely leaves an upside bias to estimates.
Citi
Buy
maintain
$330 -> $355
2025-05-08
Reason
Citi
Price Target
$330 -> $355
2025-05-08
maintain
Buy
Reason
Citi raised the firm's price target on Cencora to $355 from $330 and keeps a Buy rating on the shares. The firm continues to be impressed with Cencora's U.S. results, saying they "firmly establish" the company as a "safe haven" trade amid outsized market volatility. The company posted a "beat-and-raise" quarter largely due to broad-based U.S. strength across its "well-diversified" specialty book of business, the analyst tells investors in a research note.
Baird
NULL -> Outperform
maintain
$314 -> $350
2025-05-08
Reason
Baird
Price Target
$314 -> $350
2025-05-08
maintain
NULL -> Outperform
Reason
Baird raised the firm's price target on Cencora to $350 from $314 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cencora Inc (COR.N) is 16.72, compared to its 5-year average forward P/E of 14.00. For a more detailed relative valuation and DCF analysis to assess Cencora Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
14.00
Current PE
16.72
Overvalued PE
16.10
Undervalued PE
11.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average EV/EBITDA
10.19
Current EV/EBITDA
12.39
Overvalued EV/EBITDA
11.84
Undervalued EV/EBITDA
8.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
0.13
Current PS
0.16
Overvalued PS
0.15
Undervalued PS
0.11

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2472.49% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

COR News & Events

Events Timeline

(ET)
2025-08-06
06:33:33
Cencora raises FY25 adjusted EPS view to $15.85-$16.00 from $15.70-$15.95
select
2025-08-06
06:31:58
Cencora reports Q2 adjusted EPS $4.00, consensus $3.84
select
2025-05-13 (ET)
2025-05-13
06:22:08
Trump's drug-price crackdown may lead to minor concessions, WSJ reports
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
4.5
08-07Benzinga
Wall Street Recovers, Apple Rallies 6% On $100-Billion Gov Manufacturing Investment: What's Moving Markets Wednesday?

  • Market Performance: U.S. stocks rebounded sharply on Wednesday, driven by strong corporate earnings and investor optimism, with the S&P 500 rising 0.8% and the Nasdaq 100 climbing 1.2%, while small caps saw a slight decline.

  • Apple's Surge: Apple Inc. led the market gains, jumping nearly 6% following the announcement of a $100 billion manufacturing investment plan by the White House, which is perceived as potentially favorable for the company's tariff situation despite ongoing trade tensions.

Preview
7.0
08-07Benzinga
Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

  • Financial Performance: Cencora, Inc. reported an 8.7% increase in third-quarter 2025 sales to $80.66 billion, driven by growth in both U.S. and International Healthcare Solutions segments, with adjusted earnings rising 19.8% year-over-year to $4.00 per share.

  • Updated Guidance: The company revised its fiscal year 2025 financial guidance, expecting adjusted earnings between $15.85-$16.00 and sales around $320.31 billion, reflecting stronger growth projections for its U.S. Healthcare Solutions segment.

Preview
7.0
08-07Yahoo Finance
Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

  • Cencora's Financial Performance: Cencora, Inc. reported a third-quarter 2025 sales increase of 8.7% to $80.66 billion, driven by growth in both U.S. and International Healthcare Solutions segments, with adjusted earnings rising 19.8% year-over-year.

  • Updated Financial Guidance: The company has revised its fiscal year 2025 financial guidance, expecting adjusted earnings between $15.85-$16.00 and sales around $320.31 billion, reflecting stronger growth projections for its U.S. Healthcare Solutions segment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cencora Inc (COR) stock price today?

The current price of COR is 285.13 USD — it has increased 2.42 % in the last trading day.

arrow icon

What is Cencora Inc (COR)'s business?

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

arrow icon

What is the price predicton of COR Stock?

Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 334.00 USD with a low forecast of 300.00 USD and a high forecast of 355.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cencora Inc (COR)'s revenue for the last quarter?

Cencora Inc revenue for the last quarter amounts to 80.66B USD, increased 8.65 % YoY.

arrow icon

What is Cencora Inc (COR)'s earnings per share (EPS) for the last quarter?

Cencora Inc. EPS for the last quarter amounts to 3.52 USD, increased 45.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cencora Inc (COR)'s fundamentals?

The market is revising Downward the revenue expectations for Cencora, Inc. (COR) for FY2025, with the revenue forecasts being adjusted by -0.04% over the past three months. During the same period, the stock price has changed by 0.75%.
arrow icon

How many employees does Cencora Inc (COR). have?

Cencora Inc (COR) has 42000 emplpoyees as of August 10 2025.

arrow icon

What is Cencora Inc (COR) market cap?

Today COR has the market capitalization of 55.28B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free